Coherus Oncology vs Pelthos Therapeutics
CHRS and PTHS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CHRS and PTHS compare
Coherus Oncology is the larger company, worth 2.9 times as much as Pelthos Therapeutics ($78.2M against $27.4M).
Pelthos Therapeutics keeps more of each dollar of sales as profit, with a net margin of −200% compared with −259% at Coherus Oncology.
Coherus Oncology scores higher on the StockData Score (7 against 2 for Pelthos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CHRS | PTHS |
|---|---|---|
| Size and price | ||
| Market cap | $78.2M | $27.4M |
| Share price | $0.506 | $7.15 |
| Change, 1 year | −59.8% | −79.4% |
| Change, 5 years | −97.2% | – |
| Beta (5Y) | 0.81 | 0.91 |
| Employees | 147 | 92 |
| StockData Score | ||
| Total score | 7 (better) | 2 |
| Valuation score | 3 (better) | 1 |
| Growth score | 2 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.5× | 0.6× (better) |
| P/B | 1.3× | – |
| Fair value | $1.18 | – |
| Margin of safety | 57.0% | – |
| Growth | ||
| Revenue growth (TTM) | 61.0% | – |
| Revenue growth, 5Y average | −38.4% | – |
| Net income growth (TTM) | −174% | – |
| EPS growth, 5Y average | −2.5% | – |
| Profitability | ||
| Gross margin | 68.9% | 78.6% (better) |
| Operating margin | −312% | −133% (better) |
| Net margin | −259% | −200% (better) |
| Return on equity | −146% | – |
| Financial health | ||
| Interest coverage | −17.5× | −7.8× (better) |
| Current ratio | 1.77 | 1.98 (better) |
| Altman Z-score | −12.31 | −1.83 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 45.5% | 35.6% |
| Held by insiders | 1.3% | – |
| Insider net buying, 12 months | – | $794K |
| Short interest, % of float | 8.3% | – |
Go deeper
- CHRS stock overview
- CHRS income statement
- CHRS valuation and score
- PTHS stock overview
- PTHS income statement
- PTHS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.